

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **February 1, 2023**, updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at <https://www.ab.bluecross.ca/dbl/publications.html>

Please refer to the February 1, 2023, updates for complete listings of products available by special authorization, step therapy/special authorization, restricted benefit/special authorization, changes to criteria for coverage, restricted benefits, changes to benefit status, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change, discontinued products and products removed from the *ADBL*.

Please note that the online interactive Drug Benefit List (*iDBL*) at [ab.bluecross.ca/dbl/idbl_main1.php](https://www.ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Gentamicin 40 mg/mL Injection (DIN 02242652) manufactured by Sandoz Canada Inc., **Gentamicin 40 mg/mL Injection (DIN 02457008)** manufactured by Hikma Pharmaceuticals PLC (Teligent Canada, Inc.) will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **January 9, 2023**.

As of **January 9, 2023**, all claims for Gentamicin 40 mg/mL (DIN 02457008) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/providers/pharmacy-home.php](https://www.ab.bluecross.ca/providers/pharmacy-home.php)

Due to the unavailability of pms-lpratropium 0.03% Nasal Spray (DIN 02239627) manufactured by Pharmascience Inc., **Ipravent 0.06% Nasal Spray (DIN 02246084)** manufactured by AA Pharma Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **January 17, 2023**.

As of **January 17, 2023**, all claims for Ipravent 0.06% Nasal Spray (DIN 02246084) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/providers/pharmacy-home.php](https://www.ab.bluecross.ca/providers/pharmacy-home.php)

Due to the unavailability of Vyvanse 30 mg Capsule (DIN 02322951) manufactured by Takeda Canada Inc., **Vyvanse 10 mg Capsule (DIN 02439603)** manufactured by Takeda Canada Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **January 16, 2023**.

As of **January 16, 2023**, all claims for Vyvanse 10 mg Capsule (DIN 02439603) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [ab.bluecross.ca/providers/pharmacy-home.php](https://www.ab.bluecross.ca/providers/pharmacy-home.php)

continued next page

continued from previous page

Removal of Temporary Benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Teva-Codeine 30 mg Tablet (DIN 00593451) manufactured by Teva Canada Limited, Codeine 30 mg Tablet (DIN 02009757) manufactured by Laboratoire Riva Inc. was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Teva Canada Limited has advised Alberta Blue Cross that the shortage for Teva-Codeine 30 mg Tablet (DIN 00593451) has been resolved.

Codeine 30 mg Tablet (DIN 02009757) will no longer be considered a temporary benefit for the ADBL after **February 15, 2023**. The above grouping was removed from the Critical Supply Product List **January 13, 2023**.

Due to the shortage of Sandoz Fluorometholone 0.1% Ophthalmic Suspension (DIN 00432814) manufactured by Sandoz Canada Inc., FML Liquifilm 0.1% Ophthalmic Suspension (DIN 00247855) manufactured by Abbvie Corporation was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Alberta Blue Cross confirms that the shortage for Sandoz Fluorometholone 0.1% Ophthalmic Suspension (DIN 00432814) has been resolved at McKesson.

FML Liquifilm 0.1% Ophthalmic Suspension (DIN 00247855) will no longer be considered a temporary benefit for the ADBL after **February 23, 2023**. The above grouping was removed from the Critical Supply Product List **January 25, 2023**.

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage for pms-Fluticasone HFA 125 mcg/dose Metered Dose Aerosol (DIN 02503123) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 20, 2023**. The following grouping was removed from the Critical Supply Product List **January 19, 2022**.

FLUTICASONE PROPIONATE

125 MCG / DOSE METERED DOSE AEROSOL

00002478897	PMS-FLUTICASONE HFA	PMS	\$ 0.2926
00002014327	FLOVENT HFA	GSK	\$ 0.3762

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

